On the Hunt for Biomarkers


Biomarker development, from detection to validation, has become a cornerstone in the field of quantitative proteomics. The ability to decipher the presence of signature peptides as surrogates for low- to mid-abundance proteins indicative of disease states carries enormous inherent potential for cancer diagnostics, prognostics, and therapeutics. Consider the deluge of papers published in the last 12 months suggesting candidate biomarkers: a PubMed search for papers associated with the term "potential biomarker" in 2009 yields more than 7,800 results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.